A THERAPEUTIC DRUG-MONITORING APPROACH FOR DALBAVANCIN (MONTALBANO)
Simona Landonio(ASST Fatebenefratelli Sacco), Andrea Gori(University of Milan), Chiara Mariani, Dario Cattaneo(ASST Fatebenefratelli Sacco), Alice Covizzi(ASST Fatebenefratelli Sacco), Matteo Passerini(University of Milan), Massimo Coen(ASST Fatebenefratelli Sacco), Stefania Merli(University of Pavia), Lucia Galli(University of Milan), Riccardo De Giorgi(Warneford Hospital)
Cited by 0
Related Papers
Immune deficiency is a risk factor for severe COVID‐19 in people living with HIV
|HIV Medicine|2020|166
Anemia in patients with Covid-19: pathogenesis and clinical significance
|Clinical and Experimental Medicine|2021|154
Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study
|The Lancet Infectious Diseases|2023|137
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
|Journal of Hepatology|2018|133
Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2000|115